Phase I Study of Proteolysis-Targeting Chimera Degrader ARV-110 in Metastatic Castration-Resistant Prostate Cancer

May 29-31, 2020; Online at meetings.asco.org/am
ARV-110, a proteolysis-targeting chimera, shows promising clinical activity in heavily pretreated mCRPC patients who have received at least 1 second-generation AR therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Von Experten verfasster Kommentar zu Kombinationstherapien mit PARP-Inhibitoren und anderen Wirkstoffen bei fortgeschrittenem Prostatakrebs von Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Commento di un esperto sulle terapie di combinazione che utilizzano inibitori PARP più altri agenti come Opzioni di cura clinica (Clinical Care Options, (CCO), nel cancro alla prostata avanzato.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

臨床ケアオプション (CCO)による、前立腺進行がんに対するRARP阻害薬と他の薬剤を使用した組み合わせ治療に関する専門家が書いたコメント

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Comentario de un experto sobre las terapias de combinación que utilizan inhibidores de PARP más otros agentes en el cáncer de próstata avanzado de Clinical Care Options (CCO).

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue